Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Cancer Research

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 11106230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein

  1999cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

  1996cited by this paper
• Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.

  1996influential reference
• P-glycoprotein--a mediator of multidrug resistance in tumour cells.

  1996cited by this paper
• Clinical trials of agents that reverse multidrug resistance. A literature review

  1993cited by this paper
• In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

  1991cited by this paper
• Clinical trials of agents that reverse multidrug-resistance.

  1989cited by this paper

• Repurposing the Tyrosine Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Cancer Therapy: A Comprehensive Review

  2025cites this paper
• The Potential of Phytochemicals to Overcome Multidrug Resistance in Metastatic Melanoma

  2025cites this paper
• Targeting Type III Secretion System using Salmonella: A Promising Candidate for Innovative Antibacterial Therapy

  2025cites this paper
• Highly Potent and Intestine Specific P-Glycoprotein Inhibitor to Enable Oral Delivery of Taxol.

  2024cites this paper
• ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain

  2024cites this paper
• ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery

  2023cites this paper
• Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines

  2022cites this paper
• ATP binding cassette transporters and cancer: revisiting their controversial role.

  2021cites this paper
• Role of ABCB1 in Mediating Chemo-resistance of Triple Negative Breast Cancers.

  2021cites this paper
• Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer

  2020cites this paper
• Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

  2020cites this paper
• Role of ATP-Binding Cassette Transporter Proteins in CNS tumors: Resistance-based perspectives and clinical updates.

  2020cites this paper
• Dynamic induction of drug resistance through a stress-responsive enhancer in acute myeloid leukemia

  2019influential citation
• A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia

  2019influential citation
• Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators

  2019cites this paper
• Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

  2019cites this paper
• Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration

  2018cites this paper
• Coadministration of antiepileptic drugs and P-glycoprotein inhibitors of flavonoid-type

  2018cites this paper
• Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy

  2018cites this paper
• Bioenergetic coupling in P-glycoprotein: determining the relative position, topography and role of transmembrane helices six and twelve

  2018cites this paper
• Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport

  2017cites this paper
• Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies

  2017cites this paper
• A newly synthesized nickel chelate can selectively target and overcome multidrug resistance in cancer through redox imbalance both in vivo and in vitro

  2017cites this paper
• Influence of the dual combination of silymarin and (-)-epigallocatechin gallate, natural dietary flavonoids, on the pharmacokinetics of oxcarbazepine in rats.

  2017cites this paper
• Design and Synthesis of New Selective P-gp Substrates and Inhibitors.

  2016cites this paper
• Increasing nerve agent treatment efficacy by P-glycoprotein inhibition.

  2016cites this paper
• Cancer stem cell targets - a review.

  2016cites this paper
• P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy

  2016cites this paper
• Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer.

  2016cites this paper
• Changed expression and function of P-gp in peripheral blood CD56 + cells predicting chemoresistance in non-Hodgkin lymphoma patients

  2015cites this paper
• Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

  2015cites this paper
• Cancer and cancer stem cell targeting agents : A focus on salinomycin and apoptin

  2015cites this paper
• Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.

  2015cites this paper
• Increased Permeability-Glycoprotein Inhibition at the Human Blood–Brain Barrier Can Be Safely Achieved by Performing PET During Peak Plasma Concentrations of Tariquidar

  2015cites this paper
• Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway

  2015cites this paper
• Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches.

  2014cites this paper
• L-1416, a novel MDR reversing agent with possible reduced calcium antagonism

  2014cites this paper
• Increased P-gp inhibition at the human blood brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar

  2014cites this paper
• In Silico Screening for Inhibitors of P-Glycoprotein That Target the Nucleotide Binding Domains

  2014cites this paper
• ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

  2014cites this paper
• Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar

  2013cites this paper
• Synthesis and Molecular Modeling Studies of Bicyclic Inhibitors of Dihydrofolate Reductase, Receptor Tyrosine Kinases and Tubulin

  2013cites this paper
• ABC-transportørenes kliniske betydning MED-3950 5.-årsoppgave - Profesjonsstudiet i medisin ved Universitetet i Tromsø

  2013cites this paper
• Möglichkeiten der Überwindung von Chemoresistenz beim kindlichen Rhabdomyosarkom

  2013cites this paper
• DMD049577 683..688

  2013cites this paper
• A Selective ATP-Binding Cassette Subfamily G Member 2 Efflux Inhibitor Revealed via High-Throughput Flow Cytometry

  2013cites this paper
• Retrospective Analysis of P-Glycoprotein–Mediated Drug-Drug Interactions at the Blood-Brain Barrier in Humans

  2013cites this paper
• FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters.

  2013influential citation
• Small and Innovative Molecules as New Strategy to Revert MDR

  2013cites this paper
• Pgp‐Mediated Interaction Between (R)‐[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data

  2012cites this paper
• Investigational ABC transporter inhibitors

  2012cites this paper
• Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin

  2012cites this paper
• Synthesis of a Dual Functional Anti-MDR Tumor Agent PH II-7 with Elucidations of Anti-Tumor Effects and Mechanisms

  2012cites this paper
• The molecular interaction of a copper chelate with human P-glycoprotein

  2012cites this paper
• Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

  2012cites this paper
• Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer

  2012cites this paper
• Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects

  2012cites this paper
• Pharmacological properties of radiotracers that measure p-glycoprotein function and density

  2012cites this paper
• Small Molecule Drugs and Targeted Therapies for Neuroblastoma

  2012cites this paper
• Cancer Therapy: Clinical A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

  2011cites this paper
• The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

  2011cites this paper
• Chalcogenopyrylium Dyes as Modulators of Multidrug Resistance Protein (MRP) 1

  2011cites this paper
• P-glycoprotein inhibition: the past, the present and the future.

  2011cites this paper
• Increasing oxime efficacy by blood-brain barrier modulation.

  2011cites this paper
• The controversial role of ABC transporters in clinical oncology.

  2011cites this paper
• New tariquidar-like ABCB1 modulators in cancer chemotherapy:Preclinical pharmacokinetic, pharmacodynamic investigations and computational studies

  2010cites this paper
• A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

  2010cites this paper
• Loperamide and P‐glycoprotein inhibition: assessment of the clinical relevance

  2010cites this paper
• P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide

  2010cites this paper
• Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines

  2010cites this paper
• Reversing agents for ATP-binding cassette drug transporters.

  2010cites this paper
• Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET

  2010cites this paper
• Development of dual-acting prodrugs for circumventing multidrug resistance.

  2009cites this paper
• Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.

  2009cites this paper
• A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET

  2009cites this paper
• Small Molecule MRP1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Model of Neuroblastoma

  2009cites this paper
• Generating Inhibitors of P-Glycoprotein: Where to, Now?

  2009cites this paper
• Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.

  2009cites this paper
• A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine

  2009cites this paper
• Multidrug Resistance Mediated by MDR-ABC Transporters

  2009cites this paper
• Chemotherapy in Mouse Models of Neuroblastoma Inhibitor Reversan Increases the Therapeutic Index of Associated Protein 1 − Small-Molecule Multidrug Resistance

  2009cites this paper
• Reversion of P-glycoprotein-mediated multidrug resistance in human leukemic cell line by carnosic acid.

  2008cites this paper
• Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein

  2008cites this paper
• One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures

  2008cites this paper
• In vivo site-directed radiotracers: a mini-review.

  2008cites this paper
• New-generation efflux pump inhibitors

  2008cites this paper
• Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice

  2008cites this paper
• Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

  2008cites this paper
• Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress.

  2007cites this paper
• Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

  2007cites this paper
• Chemotherapy-induced resistance by ATP-binding cassette transporter genes.

  2007cites this paper
• Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.

  2007cites this paper
• How can we best use structural information on P-glycoprotein to design inhibitors?

  2007cites this paper
• Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes.

  2007cites this paper
• The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2

  2007cites this paper
• The Blood‐Brain Barrier: Roles of the Multidrug Resistance Transporter P‐Glycoprotein

  2007cites this paper
• The role of the blood-brain barrier and multidrug transporters in pharmacoresistant epilepsy : studies in a rat model for temporal lobe epilepsy

  2007cites this paper
• Curcumin as chemosensitizer.

  2007cites this paper
• Schisandrol A from Schisandra chinensis Reverses P-Glycoprotein-Mediated Multidrug Resistance by Affecting Pgp-Substrate Complexes

  2007cites this paper
• Role of drug efflux carriers in the healthy and diseased brain

  2006cites this paper